Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Nektar is a clinical-stage biopharmaceutical company developing drug candidates using proprietary PEGylation and advanced polymer conjugate technology platforms. The company focuses on oncology, pain, anti-infectives, and immunology. Key proprietary candidates include NKTR-118 (partnered with AstraZeneca for opioid-induced constipation) and NKTR-102 (a topoisomerase I inhibitor for various cancers). The company also generates revenue through licensing and manufacturing agreements with partners such as Amgen, Roche, and Bayer.
Key Financial Metrics
| Metric (in thousands) | 2010 | 2009 |
|---|---|---|
| Total Revenue | $159,039 | $71,931 |
| Net Loss | $(37,938) | $(102,519) |
| Loss Per Share (Basic & Diluted) | $(0.40) | $(1.11) |
| Research & Development Expense | $108,065 | $95,109 |
| Cash, Cash Equivalents & Investments | $315,932 | $396,211 |
| Convertible Subordinated Notes (Debt) | $214,955 | $214,955 |
| Working Capital | $289,871 | $260,650 |
Liquidity: As of December 31, 2010, the company held approximately $315.9 million in cash and short-term investments. Total indebtedness was approximately $240.4 million, primarily consisting of $215.0 million in convertible notes due September 2012.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 121% to $159.0 million in 2010 compared to $71.9 million in 2009. This was primarily driven by the recognition of $101.4 million of the $125.0 million upfront payment received from AstraZeneca in late 2009 for the NKTR-118 and NKTR-119 license agreement. AstraZeneca represented 68% of total revenue in 2010.
- Improved Net Loss: Net loss narrowed significantly to $37.9 million in 2010 from $102.5 million in 2009, largely due to the revenue recognition mentioned above.
- Impairment Charge: The company recorded a $12.6 million impairment charge in 2010 related to the relocation of its corporate headquarters and R&D operations from San Carlos to a new facility in Mission Bay, San Francisco. This charge was not present in 2009.
- R&D Expenses: R&D expenses increased 14% to $108.1 million, driven by increased headcount, stock-based compensation, and facility costs, partially offset by lower outside service costs for partnered programs.
Guidance, Outlook, and Risks
Outlook and Strategy:
- NKTR-102 Development: Management announced plans to advance NKTR-102 into Phase 3 clinical development for metastatic breast cancer and platinum-resistant/refractory ovarian cancer without a collaboration partner, bearing the majority of development costs. Phase 3 trials are expected to begin in late 2011.
- Revenue Expectations: Management expects license, collaboration, and other revenue to substantially decrease in 2011 as the upfront payment from AstraZeneca has been fully recognized.
- Capital Needs: The company stated it does not have sufficient resources to fund its R&D pipeline, complete late-stage development of NKTR-102, and repay its $215 million convertible notes due in September 2012. It plans to explore restructuring the notes or raising additional capital.
Subsequent Event: On January 24, 2011, the company completed a public offering of common stock, raising approximately $220.4 million in net proceeds.
Key Risks:
- Liquidity and Debt: Significant risk of inability to repay $215 million in convertible notes due in 2012 without restructuring or additional financing.
- Clinical Trial Failure: High risk of failure in clinical trials for proprietary candidates (NKTR-102, NKTR-181) and partnered programs (Amikacin Inhale).
- Customer Concentration: Heavy reliance on AstraZeneca, which accounted for 68% of 2010 revenue.
- Manufacturing: Delays in finalizing device design for Amikacin Inhale have pushed back Phase 3 trials.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $215 million convertible notes due September 2012 and any progress on restructuring or refinancing.
- NKTR-102 Phase 3 Costs: Confirm the estimated budget and timeline for the self-funded Phase 3 trials of NKTR-102, as this will be a major cash drain.
- Revenue Sustainability: Assess the pipeline of future milestone payments and royalties to replace the one-time AstraZeneca revenue recognized in 2010.
- Amikacin Inhale Status: Monitor updates on the device design finalization and the start date of Phase 3 trials with Bayer.
- Stock Offering Impact: Review the dilution impact of the January 2011 stock offering and the specific use of the $220.4 million raised.